NAMS — NewAmsterdam Pharma NV Income Statement
0.000.00%
- $1.73bn
- $1.25bn
- $14.09m
Annual income statement for NewAmsterdam Pharma NV, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | IFRS | USG | USG | USG |
Status: | fx Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0 | 0 | 103 | 14.1 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Depreciation and Amortization | ||||
Unusual Expense / Income | ||||
Other Operating Expenses | ||||
Total Operating Expenses | 6.19 | 35.9 | 106 | 197 |
Operating Profit | -6.19 | -35.9 | -3.56 | -183 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -6.55 | -41.8 | -22.6 | -177 |
Provision for Income Taxes | ||||
Net Income After Taxes | -6.55 | -41.8 | -22.6 | -177 |
Net Income Before Extraordinary Items | ||||
Net Income | -6.55 | -41.8 | -22.6 | -177 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -6.55 | -41.8 | -22.6 | -177 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.08 | -3.73 | -1.19 | -2.15 |
Dividends per Share |